

Special Issue

Applications and Developments of Metal-Based Drugs

Message from the Guest Editor

Metal complexes, such as platinum derivatives for anticancer therapy and gold compounds for treating rheumatoid arthritis, demonstrate their diverse therapeutic potential. Metal complexes possess unique chemical structures and reactivities that can be finely tuned with ligand frameworks and oxidation states, offering advantages over traditional organic drugs. This Special Issue of *Biomedicines* focuses on the latest innovations in the field. It welcomes contributions related to the design, synthesis and optimization of metal complexes for use as therapeutic and diagnostic tools. The emphasis is on understanding the mechanisms of action, identifying *in vivo* targets and optimizing delivery methods using carriers such as nanoparticles or liposomes. Furthermore, the Special Issue explores the role of metal complexes in molecular imaging, particularly radiopharmaceuticals for investigating various diseases. By providing a dedicated platform for interdisciplinary research, the Special Issue aims to advance knowledge and promote new strategies in inorganic medicinal chemistry to facilitate the clinical translation of such compounds in the future.

Guest Editor

Dr. Sajal Sen

Department of Biological Engineering, Massachusetts Institute of Technology, 32 Vassar Street, Cambridge, MA 02139, USA

Deadline for manuscript submissions

closed (31 January 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/210821

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).